Kura Oncology (NASDAQ:KURA) Share Price Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• Kura Oncology shares crossed above their 50‑day moving average, trading as high as $9.61 and last at $9.32 versus a 50‑day MA of $8.79 (still slightly below the 200‑day MA of $9.47), indicating short‑term technical strength.
• Analyst sentiment remains largely positive—10 Buys, 2 Holds and 1 Sell—yielding a consensus "Moderate Buy" rating and an average price target of $26.38, though several firms have trimmed targets recently.
• Recent fundamentals are weak: Kura missed quarterly EPS ($‑0.92 vs. $‑0.72 expected) and revenue ($17.34M vs. $34.71M), posted large negative margins and ROE, and sell‑side forecasts expect negative full‑year EPS (‑3.36).

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $8.79 and traded as high as $9.61. Kura Oncology shares last traded at $9.32, with a volume of 947,506 shares traded.

Analysts Set New Price Targets

A number of research analysts have weighed in on KURA shares. Mizuho reduced their target price on Kura Oncology from $30.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 24th. UBS Group reiterated a "buy" rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Leerink Partners set a $20.00 target price on Kura Oncology and gave the stock an "outperform" rating in a report on Tuesday, January 13th. Zacks Research upgraded Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Thursday, February 26th. Finally, Wedbush reduced their target price on Kura Oncology from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday, March 6th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $26.38.

Kura Oncology Stock Performance

The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06. The business has a 50-day moving average price of $8.79 and a 200 day moving average price of $9.47. The stock has a market capitalization of $827.24 million, a P/E ratio of -2.93 and a beta of 0.32.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.The company had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million. As a group, sell-side analysts forecast that Kura Oncology, Inc. will post -3.36 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc lifted its position in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after acquiring an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company's stock valued at $34,000 after acquiring an additional 3,072 shares in the last quarter. Allworth Financial LP lifted its position in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company's stock valued at $60,000 after acquiring an additional 3,769 shares in the last quarter. Finally, Merit Financial Group LLC bought a new position in Kura Oncology in the 3rd quarter valued at approximately $89,000.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.